Which of the following is a therapeutic use of Fresh Frozen Plasma (FFP)?

Fresh Frozen Plasma (FFP) is primarily used in therapeutic contexts to replace clotting factors in patients who have deficiencies or are at risk of bleeding. It contains various coagulation factors, including fibrinogen, prothrombin, and factors V, VII, VIII, IX, and X, which are essential for proper blood clotting. Therefore, when FFP is administered, it effectively increases the levels of these clotting factors in the patient’s circulation, thereby aiding in the prevention or management of bleeding complications, particularly in conditions such as liver disease, disseminated intravascular coagulation (DIC), or after massive transfusions.

In therapeutic scenarios that require addressing clotting factor deficiencies, preferring FFP makes sense because it provides a broad range of factors in a single transfusion, rather than administering individual clotting factor concentrates, which might be necessary in specific cases only.

The other options do not accurately reflect the established uses of FFP. Decreasing blood volume is counterproductive in clinical settings where plasma is typically administered to expand volume and improve clotting. While FFP contains some proteins involved in red blood cell production and immunity, the primary focus is not on enhancing erythropoiesis or recovering white blood cells, making these